Birchview Capital »

Lipocine shares owned by Birchview Capital

Quarter-by-quarter ownership of Lipocine (LPCN) shares owned by Birchview Capital from 13F filings

Historical chart of Birchview Capital investment in Lipocine

Tip: Access up to 7 years of quarterly data

All positions including Lipocine held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lipocine by Birchview Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $893k 112k 7.99

More positions owned by Birchview Capital

Kla Corporation Com New (KLAC)
Bristol Myers Squibb (BMY)
Compass Therapeutics (CMPX)
Lam Research Corporation Com New (LRCX)
Stoke Therapeutics (STOK)
Encana Corporation (OVV)
Intellia Therapeutics (NTLA)
Structure Therapeutics Spons Adr (GPCR)
Solid Biosciences Com New (SLDB)
Prothena Corp SHS (PRTA)
Biodesix
ACADIA Pharmaceuticals (ACAD)
Protagonist Therapeutics (PTGX)
Neurocrine Biosciences (NBIX)
Olema Pharmaceuticals (OLMA)

View all positions for Birchview Capital

Top funds holding Lipocine

Ikarian Capital
Squadron Capital Management
Diadema Partners
Vanguard Group
Vanguard Capital Management
AIGH Capital Management
Stempoint Capital
Boothbay Fund Management
Seven Fleet Capital Management
Birchview Capital
BlackRock
Mink Brook Asset Management
Geode Capital Management
Renaissance Technologies
Two Sigma Investments

View all funds holding Lipocine